BackChromadex Overview

Chromadex Profit Margin

Valuation check: CDXC's profit margin is 17.97%, above the Healthcare sector average of 17.63%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-4.31%

As of Sep 2026

Annual Profit Margin (TTM)

17.97%
↓ 74.38% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Chromadex (CDXC) FAQ

Chromadex posts a profit margin of 17.97% as of September 2026. That compares with 70.14% in the prior-year period — down 74.4% year over year. That is above the Healthcare sector average of 17.63%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Chromadex's profit margin was 70.14%. The latest reading is 17.97% — a 74.4% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 17.63% is typical. Chromadex's 17.97% is higher that level. That is roughly 1.9% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Chromadex's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 17.97% as of September 2026; use YoY and peer views to separate noise from signal.

Context for CDXC's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 17.63%), and (3) consistency with growth and profitability. This page covers the first two; Chromadex's other metric pages and overview cover the third.